EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Feasibility and outcomes of kidney transplantation in patients with end‐stage kidney disease after haemopoietic stem cell transplantation

Bioh Kim, Seunghyeok Choi, Hanbi Lee iD, Hye-Eun Yoon iD, Hohyung Nam, Silvia Park, Byung Ha Chung iD

Internal Medicine Journal · 2026-07 · 56 (7) · 1174-1181

DOI: 10.1111/imj.70459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 20.05.2026. Verfasst von Bioh Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Rep…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Kidney Failure, Chronic, Kidney Transplantation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advances in haemopoietic stem cell transplantation (HSCT) have improved long‐term survival, but they have also led to late complications, such as nephropathy. However, the safety and feasibility of kidney transplantation (KT) in patients with HSCT‐related end‐stage kidney disease (ESKD) remain unclear.

Aim

This study aimed to evaluate the feasibility and clinical outcomes of KT in patients with ESKD following HSCT.

Methods

This study retrospectively analysed eight patients with ESKD who underwent KT following HSCT for haematologic disorders, including aplastic anaemia ( n = 5), acute myeloid leukaemia ( n = 2) and chronic myeloid leukaemia ( n = 1).

Results

The median time to progression to ESKD was 104 months after HSCT, with a median interval of 138 months between HSCT and KT. The causes of ESKD included diabetic nephropathy ( n = 1), hypertensive nephropathy ( n = 1), focal segmental glomerulosclerosis ( n = 1), thrombotic microangiopathy ( n = 1) and unknown aetiology ( n = 4), with three diagnoses confirmed through kidney biopsy. Three patients received both HSCT and KT from the same donor, allowing them to completely discontinue immunosuppressive therapy. During a median follow‐up of 55 months (range 2–143 months), there was only one case of acute T‐cell‐mediated rejection, and one patient died from sepsis due to a urinary tract infection. Notably, none of the patients experienced a recurrence of their original haematologic disease.

Conclusion

Despite concerns regarding immunosuppression and the risk of infection in this high‐risk population, both patient and graft outcomes were favourable. These findings suggest that KT is a feasible and effective treatment option for patients with ESKD following HSCT, particularly when managed with personalised strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationKidney Failure, ChronicKidney TransplantationHumansMaleFemaleAdultRetrospective StudiesFeasibility StudiesMiddle AgedTreatment OutcomeYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

kidney transplantationpost‐haematopoietic stem cell transplantationrenal outcome

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Internal Medicine, Jeonbuk National University Hospital, Jeonju, Republic of Korea.
  • Transplantation Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

ORCID-Profile: Hanbi Lee, Hye-Eun Yoon, Byung Ha Chung

Förderung

  • Korea Health Industry Development Institute
  • National Research Foundation of Korea

Zitieren

APA

Kim, B., Choi, S., Lee, H., Yoon, H. E., Nam, H., Park, S., & Chung, B. H. (2026). Feasibility and outcomes of kidney transplantation in patients with end‐stage kidney disease after haemopoietic stem cell transplantation. Internal Medicine Journal, 56(7), 1174-1181. https://doi.org/10.1111/imj.70459

Vancouver

Kim B, Choi S, Lee H, Yoon HE, Nam H, Park S, et al. Feasibility and outcomes of kidney transplantation in patients with end‐stage kidney disease after haemopoietic stem cell transplantation. Internal Medicine Journal. 2026;56(7):1174-1181. doi:10.1111/imj.70459

BibTeX
@article{Kim2026,
  author = {Kim, Bioh and Choi, Seunghyeok and Lee, Hanbi and Yoon, Hye-Eun and Nam, Hohyung and Park, Silvia and Chung, Byung Ha},
  title = {Feasibility and outcomes of kidney transplantation in patients with end‐stage kidney disease after haemopoietic stem cell transplantation},
  journal = {Internal Medicine Journal},
  year = {2026},
  volume = {56},
  number = {7},
  pages = {1174--1181},
  doi = {10.1111/imj.70459}
}
Kostenlos starten →